Search

MSK Kids is continuously investigating new ways to improve outcomes and the quality of life for pediatric patients with high-risk neuroblastoma. In this article we detail highlights of the latest clinical and molecular research advances for pediatric neuroblastoma.

… Thursday, September 25, 2025 MSK Kids has one of the largest teams of neuroblastoma experts and treats the highest volume of pediatric patients with neuroblastoma in the United States. Today, more than half of children with metastatic neuroblastoma survive, a 10-fold improvement since the 1980s, primarily

Meet the man who helped make the Gerstner Sloan Kettering Graduate School of Biomedical Sciences a reality.

… Wednesday, October 24, 2018 Ken Marians Dr. Marians welcoming GSK students and undergraduates to the Frontiers of Science program in 2011. Ken Marians and Lou Gerstner Dr. Marians with Louis V. Gerstner, Jr., GSK's Chairman, at the first commencement ceremony in 2012. graduates Dr. Marians, Mr. Gerstner

Improved understanding of the biology and molecular subtypes of non-small cell lung cancer (NSCLC) has led to the development of several biomarker-targeted therapies for patients with locally advanced and metastatic disease.

… Monday, November 11, 2019 Improved understanding of the biology and molecular subtypes of non-small cell lung cancer (NSCLC) has led to the development of several biomarker-targeted therapies for patients with locally advanced and metastatic disease. Cytotoxic chemotherapy remains an essential component

A study identifies genetic variations that alter the risk of breast cancer in women who have a certain gene mutation.

… Thursday, March 28, 2013 Summary A study identifies genetic variations that alter the risk of breast cancer in women who have a certain gene mutation. Since the first inherited genes for breast cancer were found in the mid-1990s, researchers have been looking for more-accurate ways to predict which women

Ivan Maillard, MD, PhD, has been named Head of the Division of Hematologic Malignancies within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).

… Monday, November 4, 2024 Ivan Maillard, MD, PhD , has been named Head of the Division of Hematologic Malignancies within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). A physician-scientist, Dr. Maillard is a practicing hematologist-oncologist with experience treating lymphoma

Beginning in April 2013, physician-scientist Charles Sawyers will serve as President of the American Association for Cancer Research, the world’s oldest and largest professional organization dedicated to advancing cancer research.

… Tuesday, March 20, 2012 Summary Beginning in April 2013, physician-scientist Charles Sawyers will serve as President of the American Association for Cancer Research, the world’s oldest and largest professional organization dedicated to advancing cancer research. Memorial Sloan Kettering physician-scientist

The quantity of tests and treatments a cancer patient undergoes could depend largely on where he or she receives care, according to an analysis by researchers at Memorial Sloan Kettering (MSK).

… Monday, April 6, 2015 From radioactive PET scans to costly chemotherapy doses, the quantity of tests and treatments a cancer patient undergoes could depend largely on where he or she receives care, according to an analysis by researchers at Memorial Sloan Kettering (MSK) and others, including Jeffrey

Research in blood stem cells has revealed new information about how these cells decide what to become when they divide.

… Tuesday, August 13, 2019 Summary By knocking out an important enzyme in blood stem cells, Sloan Kettering Institute investigators have found new details about how these cells decide what to become when they divide. Stem cells are defined by their ability to differentiate into other, more specialized

In a new paper, a collaborative team of MSK experts reports how a novel tool will help researchers learn more about the role of inherited hereditary mutations.

… Friday, November 5, 2021 Hereditary genetic mutations are a key cause of cancer. One recent study estimated that about 17% of patients with cancer harbor inherited defects in key cancer genes. But it is not well understood how or why — or even whether — these genetic changes contribute to cancer. Thanks

Memorial Sloan Kettering Cancer Center (MSK) today announced an innovative set of initiatives to support underserved communities in New York City who lack access to cancer screening and early detection. With critical support from longtime MSK Board Member Bruce Ratner, the Ratner Early Detection Initiative (REDI) draws from MSK’s deep experience in cancer science and discovery, community engagement, and compassionate patient care.

… Monday, May 6, 2024 Memorial Sloan Kettering Cancer Center (MSK) today announced an innovative set of initiatives to support underserved communities in New York City who lack access to cancer screening and early detection. With critical support from longtime MSK Board Member, real estate developer, and